Transgene Presents New Pre-Clinical Data at AACR on (i) the Combination of TG4010 with Immune Checkpoint Inhibitors;(ii) TG3003, an Anti-CD115 Monoclonal Antibody


Strasbourg, France, April 21, 2015 – Transgene SA (Euronext: TNG) today announced that new pre-clinical data for two of its programs – TG4010 and TG3003 – were presented at the Annual Meeting of the American Association for Cancer Research (AACR) in Philadelphia, PA USA.

New pre-clinical data support potential combinations of TG4010 and immune checkpoint inhibitors
Data with TG3003 anti-CD115 monoclonal antibody support biological activity and differentiated mode of action

A third poster reviewing the clinical experience with Transgene’s MVA platform was also presented.

Copies of these posters can be found on Transgene’s website in the “Our Pipeline/Publications” section at

Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.

Pour consulter le fichier PDF en intégralité, cliquez ici.

Pour visualiser les documents au format PDF, vous pouvez télécharger gratuitement Acrobat Reader XI.

Valeur associée
  Libellé Bourse Dernier Var. Vol.
Vous devez être membre pour ajouter des commentaires.
Devenez membre, ou connectez-vous.
Aucun commentaire n'est disponible pour l'instant